Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dihydroartemisinin + piperaquine + ivermectin + primaquine
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a multi-component antimalarial regimen developed by the University of Oxford, combining the artemisinin-based combination therapy (ACT) dihydroartemisinin-piperaquine with the endectocide ivermectin and the 8-aminoquinoline primaquine. The regimen is designed for malaria elimination efforts by simultaneously treating the infection in the human host and preventing further transmission. Dihydroartemisinin and piperaquine provide rapid and sustained clearance of blood-stage parasites. Primaquine is included for its ability to clear Plasmodium falciparum gametocytes and Plasmodium vivax hypnozoites. Ivermectin acts as a transmission-blocking agent by killing Anopheles mosquitoes that feed on treated individuals. A Phase 1 study in healthy Thai adults evaluated the safety, tolerability, and pharmacokinetic interactions of this combination, as well as its mosquito-lethal efficacy.
- Other names
- DHA-PQP + IVM + PQDihydroartemisinin-Piperaquine + Ivermectin + Primaquine
02
Targets
HemePfATP6 (Plasmodium falciparum ATP6)mETC (Parasite mitochondrial electron transport chain)GluCl (Glutamate-gated chloride channel)
Beyond the preview
Go deeper on dihydroartemisinin + piperaquine + ivermectin + primaquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dihydroartemisinin + piperaquine + ivermectin + primaquine.